Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations, SOR/2022-18
Section 19
Information — recall
Cite as Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations, SOR/2022-18, s. 19 · current to July 24, 2025 · regulation last amended February 27, 2022
Statute Watch
Get an alert when a bill in Parliament would change this section, and every time it moves.
The text
(1) A holder of a COVID-19 medical device authorization must, on or before recalling a COVID-19 medical device for which the authorization has been issued, provide the Minister with the following:
(a) the name of the device and its identifier, including the identifier of any medical device that is part of a system, test kit, medical device group, medical device family or medical device group family;
(b) the name and contact information of the manufacturer and, if applicable, the importer, as well as the name and contact information of the establishment where the device was manufactured, if different from that of the manufacturer;
(c) the reason for the recall, the nature of the defectiveness or possible defectiveness and the date on and circumstances under which it was discovered;
(d) an evaluation of the risk associated with the defectiveness or possible defectiveness;
(e) the number of affected units of the device that were manufactured or sold in Canada or imported into Canada;
(f) the period during which the affected units of the device were sold in Canada;
(g) the name of each person to whom the affected device was sold and the number of units sold to each person;
(h) a copy of any communication issued with respect to the recall;
(i) the proposed strategy for conducting the recall, including the date for beginning the recall, information as to how and when the Minister will be informed of the progress of the recall and the proposed date for its completion;
(j) the proposed action to prevent a recurrence of the problem; and
(k) the name, title and telephone number of the representative of the holder of the authorization to contact for any information concerning the recall.
(2) The holder of the authorization must, as soon as feasible after the completion of the recall, prepare and submit to the Minister a report on
(a) the results of the recall; and
(b) the action taken to prevent a recurrence of the problem.
(3) Despite subsections (1) and (2), the holder of the authorization may permit the importer of the COVID-19 medical device to prepare and submit, on the holder’s behalf, the information and material required under those subsections if the importer has the same information and material.
(4) The holder of the authorization must notify the Minister, in writing, if the holder has permitted the importer to prepare and submit the information and material with respect to the recall on the holder’s behalf.
Read the Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations on the Justice Laws Website ↗
Made under Food and Drugs Act, R.S.C. 1985, c. F-27; Patent Act, R.S.C. 1985, c. P-4.
Bills in Parliament that would change this section 0
No bill we hold would amend or repeal this section.